David MA - Eyepoint Pharmaceuticals Senior Officer

Eyepoint Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (0.3139) % which means that it has lost $0.3139 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7468) %, meaning that it created substantial loss on money invested by shareholders. Eyepoint Pharmaceuticals' management efficiency ratios could be used to measure how well Eyepoint Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.21 in 2024. Return On Capital Employed is likely to drop to -0.27 in 2024. At this time, Eyepoint Pharmaceuticals' Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 372.9 M in 2024, whereas Non Current Liabilities Total is likely to drop slightly above 17.4 M in 2024.

Similar Executives

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts. Eyepoint Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 122 people. Eyepoint Pharmaceuticals (EYPT) is traded on NASDAQ Exchange in USA. It is located in 480 Pleasant Street, Watertown, MA, United States, 02472 and employs 121 people. Eyepoint Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Eyepoint Pharmaceuticals Leadership Team

Eyepoint Stock Performance Indicators

Additional Tools for Eyepoint Stock Analysis